Crystalys Therapeutics has dosed the first patient with its once daily oral, URAT1 inhibitor dotinurad in its Phase II AMETHYST trial (NCT07535034), designed to assess dotinurad’s effectiveness in ...

Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two ...

Sobi announces positive topline results from pivotal phase 3 REDUCE 2 study of pozdeutinurad in gout: Stockholm, Sweden Saturday, May 23, 2026, 11:00 Hrs [IST] Sobi, a global biop ...

Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System (OBDS), today announced CE Certification of its enFuse on-body ...

This week, 28 th-29 th May, the Veeva R&D and Quality Summit took place in Copenhagen, Denmark. Focused on innovating together, and together advancing the industry, the Summit this year highlighted an ...

Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent ...

Sobi® (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza® (olezarsen) reduced the relative risk of acute pancreatitis events by 85% ...

Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent ...

Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal ...

Sobi (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza (olezarsen) reduced the relative ...